Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : O2nix Bio
Deal Size : Undisclosed
Deal Type : Collaboration
Synfini and O2nix Collaborate to Develop Novel FTSJ1 Cancer Therapeutics
Details : The collaboration aims to co-discover and develop novel drug candidates targeting FTSJ1, a tRNA-modifying enzyme implicated in metastatic cancer cell survival.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
June 18, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : O2nix Bio
Deal Size : Undisclosed
Deal Type : Collaboration